Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
high dose human umbilical cord-derived mesenchymal stem cells
- Development stage
- Unknown
- Lead developer
- Sclnow Biotechnology
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous, Intrathecal, Subcutaneous
01
Overview
High dose human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) are a cell-based therapy derived from umbilical cord tissue. These cells possess immunomodulatory, anti-inflammatory, and regenerative properties. They are being investigated for various conditions including multiple sclerosis, bronchopulmonary dysplasia, pulmonary fibrosis, and knee osteoarthritis. The high dose typically refers to concentrations ranging from 3.0 × 10^7 cells/kg to 5.0 × 10^7 cells/kg, compared to low doses which are typically around 1.0 × 10^6 cells/kg to 3.0 × 10^6 cells/kg.
- Other names
- high dose hUC-MSCs
Beyond the preview
Go deeper on high dose human umbilical cord-derived mesenchymal stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on high dose human umbilical cord-derived mesenchymal stem cells.